Painreform Net Income From Continuing Ops Over Time
| PRFX Stock | USD 0.69 0.02 2.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Painreform Performance and Painreform Correlation. Painreform | Build AI portfolio with Painreform Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Painreform. Anticipated expansion of Painreform directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Painreform assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Painreform using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Painreform's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Painreform's market price to deviate significantly from intrinsic value.
It's important to distinguish between Painreform's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Painreform should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Painreform's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Painreform and related stocks such as Universe Pharmaceuticals, Windtree Therapeutics, and Elevai Labs Common Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UPC | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 11.3 M | (8.7 M) | (6.2 M) | (8.7 M) | (3.7 M) | (3.3 M) | (3.1 M) |
| WINT | (24.5 M) | (24.5 M) | (37.9 M) | (46 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (32.6 M) | (67.6 M) | (39.2 M) | (20.3 M) | (1.8 M) | (2.1 M) | (2.2 M) |
| ELAB | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (784.7 K) | (1.8 M) | (4.3 M) | (4 M) | (3.6 M) | (3.8 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.3 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| PBM | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (3.2 M) | (51.2 M) | 1 M | 910.6 K | 956.1 K |
| VRAX | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (739.5 K) | (672.9 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| NCEL | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (22.7 M) | (12 M) | (26.6 M) | (30.5 M) | (32.1 M) |
| XRTX | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (474.2 K) | (3.8 M) | (629.6 K) | (1.3 M) | (1.7 M) | (7 M) | (2.2 M) | (3.3 M) | (3 M) | (3.1 M) |
Painreform and related stocks such as Universe Pharmaceuticals, Windtree Therapeutics, and Elevai Labs Common Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Painreform | PRFX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 65 Yigal Alon |
| Exchange | NASDAQ Exchange |
USD 0.69
Additional Tools for Painreform Stock Analysis
When running Painreform's price analysis, check to measure Painreform's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Painreform is operating at the current time. Most of Painreform's value examination focuses on studying past and present price action to predict the probability of Painreform's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Painreform's price. Additionally, you may evaluate how the addition of Painreform to your portfolios can decrease your overall portfolio volatility.